Differential survival of γδT cells, αβT cells and NK cells upon engagement of NKG2D by NKG2DL-expressing leukemic cells
Corresponding Author
Alessandro Poggi
Unit of Molecular Oncology and Angiogenesis, National Institute for Cancer Research, I-16132 Genoa
Tel.: +390105737207/211, Fax: +39010354282
Unit of Molecular Oncology and Angiogenesis, National Institute for Cancer Research (IST), Largo R. Benzi 10, 16132-Genoa, ItalySearch for more papers by this authorMarta Zancolli
Unit of Molecular Oncology and Angiogenesis, National Institute for Cancer Research, I-16132 Genoa
Search for more papers by this authorSilvia Boero
Unit of Molecular Oncology and Angiogenesis, National Institute for Cancer Research, I-16132 Genoa
Search for more papers by this authorSilvia Catellani
Laboratory of Oncohematology, University of Genoa, I-16132 Genoa
Search for more papers by this authorAlessandra Musso
Division of Immunology, Transplants and Infectious Diseases, Scientific Institute San Raffaele, I-20132 Milan
Search for more papers by this authorMaria Raffaella Zocchi
Division of Immunology, Transplants and Infectious Diseases, Scientific Institute San Raffaele, I-20132 Milan
Search for more papers by this authorCorresponding Author
Alessandro Poggi
Unit of Molecular Oncology and Angiogenesis, National Institute for Cancer Research, I-16132 Genoa
Tel.: +390105737207/211, Fax: +39010354282
Unit of Molecular Oncology and Angiogenesis, National Institute for Cancer Research (IST), Largo R. Benzi 10, 16132-Genoa, ItalySearch for more papers by this authorMarta Zancolli
Unit of Molecular Oncology and Angiogenesis, National Institute for Cancer Research, I-16132 Genoa
Search for more papers by this authorSilvia Boero
Unit of Molecular Oncology and Angiogenesis, National Institute for Cancer Research, I-16132 Genoa
Search for more papers by this authorSilvia Catellani
Laboratory of Oncohematology, University of Genoa, I-16132 Genoa
Search for more papers by this authorAlessandra Musso
Division of Immunology, Transplants and Infectious Diseases, Scientific Institute San Raffaele, I-20132 Milan
Search for more papers by this authorMaria Raffaella Zocchi
Division of Immunology, Transplants and Infectious Diseases, Scientific Institute San Raffaele, I-20132 Milan
Search for more papers by this authorAbstract
Herein, we show that γδT, CD8+αβT lymphocytes and natural killer (NK) cells display a different sensitivity to survival signals delivered via NKG2D surface receptor. All the three effector cell populations activate Akt1/PKBalpha through the engagement of this molecule. Upon binding to leukemic cells expressing NKG2D ligands (NKG2DL), including chronic lymphocytic leukemias treated with transretinoic acid, most γδT (>60%) and half CD8+αβT cells (about 50%) received a survival signal, at variance with the majority of NK cells (>80%) that underwent apoptosis by day 5. Interestingly, oligomerization of NKG2D in γδT or CD8+αβT cells, led to a significant rise in nuclear/cytoplasmic ratio of both NF-kBp52 and RelB, the two NF-kB subunits mainly involved in the transcription of antiapoptotic proteins of the Bcl family. Indeed, the ratio between the antiapoptotic protein Bcl-2 or Bcl-xL and the proapoptotic protein Bax raised in γδT or CD8+αβT cells following NKG2D engagement by specific monoclonal antibodies or by NKG2DL expressing leukemic cells. Conversely, nuclear translocation of NF-kBp52 or RelB did not increase, nor the Bcl-2/Bax or the Bcl-xL/Bax ratios changed significantly, in NK cells upon oligomerizaton of NKG2D. Of note, transcripts for α5 importin, responsible for nuclear translocation of NF-kBp52/Rel B heterodimer, are significantly higher in γδT and CD8+αβT cells than in NK cells. These biochemical data may explain, at least in part, why γδT and CD8+αβT cells are cytolytic effector cells more resistant to target-induced apoptosis than NK cells.
Supporting Information
Additional Supporting Information may be found in the online version of this article.
Filename | Description |
---|---|
IJC_25682_sm_suppfig-S1.tif86.2 KB | Supporting Figure S1 |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1 Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 2007; 7: 329–39.
- 2 Ferrarini M, Ferrero E, Dagna L, Poggi A, Zocchi MR. Human γδT cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol 2002; 23: 14–17.
- 3 Bonneville M, Scotet E. Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol 2006; 18: 539–46.
- 4 Kabelitz D, Wesch D, He W. Perspectives of gammadelta T lymphocytes in tumor immunology. Cancer Res 2007; 67: 5–8.
- 5 Kapp M, Rasche L, Einsele H, Grigoleit GU. Cellular therapy to control tumor progression. Curr Opin Hematol 2009; 16: 437–43.
- 6 Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 2000; 1: 119–26.
- 7 Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE, Hayday AC. Regulation of cutaneous malignancy by gamma delta T cells. Science 2001; 294: 605–09.
- 8 Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008; 27: 5944–58.
- 9 Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rael and HL60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001; 413: 165–71.
- 10 Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by γδ T cells. Science 1998; 279: 1737–40.
- 11 Bauer S, Groh V, Wu J, Phillips JH, Lanier LL, Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MIC-A. Science 1999; 285: 727–29.
- 12 Cosman D, Mullberg J., Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ. ULBPs, novel MHC class-I-related molecules, bind to CMV glicoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001; 14: 123–133.
- 13 Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nature Rev Immunol 2003; 3: 781–90.
- 14 Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999; 96: 6879–84.
- 15 Catellani S, Poggi A, Bruzzone A, Dadati P, Ravetti JL, Gobbi M, Zocchi MR. Expansion of Vdelta1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas ex pressing UL-16-binding proteins. Blood 2007; 109: 2078–85.
- 16 Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, Steinle A. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003; 102: 1389–96.
- 17 Cerwenka A, Bakker AB, McClanahan T, Wagner J, Wu J, Phillips JH, Lanier LL. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 2000; 12: 721–27.
- 18 Poggi A, Venturino C, Catellani S, Clavio M, Miglino M, Gobbi M, Steinle A, Ghia P, Stella S, Caligaris-Cappio F, Zocchi MR. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res 2004; 64: 9172–9179.
- 19 Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Steinle A, Salih HR. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005; 65: 6321–29.
- 20 Rohner A, Langenkamp U, Siegler U, Kalberer CP, Wodnar-Filipovicz A. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Leuk Res 2007; 31: 1393–402.
- 21 Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M, Zocchi MR. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia 2009; 23: 641–48.
- 22 Gross O, Group C, Steinberg C, Zimmermann S, Strasser D, Hannessclagher N, Reindl W, Johnsson H, Huo H, Littman DR, Peschel C, Yokoyama WM, et al. Multiple ITAM-coupled NK-cell receptors engage tha Bcl10/Malt1 complex via Carma1 for NF-kB and MAPK activation to selectively control cytokine production. Blood 2008; 112: 2421–28.
- 23 Ferrarini M, Consogno G, Rovere P, Sciorati C, Dagna L, Resta D, Rugarli C, Manfredi AA. Inhibition of caspases maintains the antineoplastic function of gammadelta T cells repeatedly challenged with lymphoma cells. Cancer Res 2001; 61: 3092–95.
- 24 Spaggiari GM, Contini P, Dondero A, Carosio R, Puppo F, Indiveri F, Zocchi MR, Poggi A. Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction. Blood 2002; 100: 4098–107.
- 25 Contini P, Zocchi MR, Pierri I, Albarello A, Poggi A. In vivo apoptosis of CD8+ lymphocytes in acute myeloid leukemia patients: involvement of soluble HLA-I and Fas ligand. Leukemia 2007; 21: 253–60.
- 26 Groh V, Wu J, Yee C, Spies T. Tumor-derived soluble MIC ligands impair expression of NKG2D and T cell activation. Nature 2002; 419: 734–38.
- 27 Doubrovina ES, Doubrovin MM, Vider E, Sisson RB, O'Reilly RJ, Dupont B, Vyas YM. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 2003; 171: 6891–99.
- 28 Jinushi M, Takehara T, Tatsumi T, Hiramatsu N, Sakamori R, Yamaguchi S, Hayashi N. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol 2005; 43: 1013–20.
- 29 Poggi A, Contini P, Catellani S, Setti M, Murdaca G, Zocchi MR. Regulation of γδT cell survival by soluble HLA-I. Involvement of CD8 and activating killer Ig-like receptors. Eur J Immunol 2005; 35: 2670–78.
- 30 Waldhauer I, Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 2006; 66: 2520–26.
- 31 Poggi A, Catellani S, Bruzzone A, Caligaris-Cappio F, Gobbi M, Zocchi MR. Lack of the leukocyte-associated Ig-like receptor-1 expression in high-risk chronic lymphocytic leukaemia results in the absence of a negative signal regulating kinase activation and cell division. Leukemia 2008; 22: 980–88.
- 32 Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cavé H, Pane F, Aerts JL, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia 2003; 17: 2318–57.
- 33 Fleige S, Walf W, Huch S, Prgomet C, Sehm J, Pfaffl MW. Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR. Biotechnol Lett 2006; 28: 1601–13.
- 34 Poggi A, Massaro AM, Negrini S, Contini P, Zocchi MR. Tumor-induced apoptosis of human IL-2-activated NK cells: role of natural cytotoxicity receptors. J Immunol 2005; 174: 2653–60.
- 35 Fuller CL, Ravichandran KS, Braciale VL. Phosphatidylinositol 3-kinase-dependent and -independent cytolytic effector functions. J Immunol 1999; 162: 6337–40.
- 36 Jiang K, Zhong B, Gilvary DL, Corliss BC, Hong-Geller E, Wei S, Djeu JY. Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nat Immunol 2000; 1: 419–25.
- 37 Ferrero E, Belloni D, Contini P, Foglieni C, Ferrero ME, Fabbri M, Poggi A, Zocchi MR. Transendothelial migration leads to protection from starvation-induced apoptosis in CD34+CD14+ circulating precursors: evidence for PECAM-1 involvement through Akt/PKB activation. Blood 2003; 101: 186–93.
- 38 Turco MC, Romano MF, Petrella A, Bisogni R, Tassone P, Venuta S. NF-kappaB/Rel-mediated regulation of apoptosis in hematological malignancies and normal hematopoietic progenitors. Leukemia 2004; 18: 11–17.
- 39 Jiang HY, Petrovas C, Sonenshein GE. RelB-p50 NF-kappa B complexes are selectively induced by cytomegalovirus immediate-early protein 1: differential regulation of Bcl-x(L) promoter activity by NF-kappa B family members. J Virol 2002; 76: 5737–47.
- 40 Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, Korsmeyer SJ. BCL-2, BCL-XL sequester BH3 domain-only molecules preventing Bax- and Bak-mediated mitochondrial apoptosis. Mol Cell 2001; 8: 705–11.
- 41 Grimm T, Schneider S, Naschberger E, Huber J, Guenzi E, Kieser A, Reitmeir P, Schulz TF, Morris CA, Stürzl M. EBV latent membrane protein-1 protects B cells from apoptosis by inhibition of BAX. Blood 2005; 105: 3263–69.
- 42 Gross A, Jockel J, Wei MC, Korsmeyer SJ. Enforced dimerization of BAX results in its translocation, mitochondrial disfunction and apoptosis. EMBO J 1998; 17: 3878–85.
- 43 Torgerson TR, Colosia AD, Donahue JP, Lin YZ, Hawiger J. Regulation of NF-kappa B, AP-1, NFAT, and STAT1 nuclear import in T lymphocytes by noninvasive delivery of peptide carrying the nuclear localization sequence of NF-kappa B p50. J Immunol 1998; 161: 6084–92.
- 44 Fagerlund R, Melen K, Cao X, Julkunen I. NF-kB p52, RelB and cRel are transported into the nucleus via a subset of importin α molecules. Cell Signal 2008; 20: 1442–51.
- 45 Strid J, Roberts SJ, Filler RB, Lewis JM, Kwong BY, Schpero W, Kaplan DH, Hayday AC, Girardi M. Acute up-regulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogensis. Nat Immunol 2008; 9: 146–54.
- 46 Hayday AC. Gammadelta T cells and the lymphoid stress-surveillance response. Immunity 2009; 31: 184–96.
- 47 Maccalli C, Pende D, Castelli C, Mingari MC, Robbins PF, Parmiani G. NKG2D engagement of colorectal cancer-specific T cells strengthen TCR-mediated antigen stimulation and elicit TCR-independent anti-tunor activity. Eur J Immunol 2003; 33: 2033–2043.
- 48 Weng N-p, Akbar AN, Goronzy J. CD28-T cells: their role in the age-associated decline of immune function. Trend Immunol 2009; 30: 306–312.